Treats major depressive disorder (MDD). ANDA 214691, held by Ajanta Pharma. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 214691 (Venlafaxine Hydrochloride), held by Ajanta Pharma, was first approved by FDA on Apr 12, 2023, with 1 approved supplement and 0 published complete response letters.
Venlafaxine extended-release tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) Social Anxiety Disorder (SAD) 1.1 Major Depressive Disorder Venlafaxine extended-release tablets are indicated for the treatment of major depressive disorder (MDD). Efficacy of venlafaxine in MDD was shown in both short-term trials and a longer-term trial in MDD.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 12, 2023 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 37.5MG BASE ยท tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE ยท tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 150MG BASE ยท tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 225MG BASE ยท tablet, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Feb 20, 2024 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Apr 12, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters